Article

Zealand Pharma aims to utilize artificial intelligence (AI) to enhance drug development for metabolic diseases, including severe obesity. CEO Adam Steensberg highlighted the company's 25 years of experience in discovering drug candidates during the JP Morgan health conference in San Francisco.

Zealand Pharma announced its strategy to build 'the world's most valuable pipeline' for metabolic diseases and recently secured access to DCAI's supercomputer Gefion to boost innovation. The company targets advancing over ten drug candidates into clinical development within the next five years, supported by a strong financial position of over $2.5 billion. Key projects include partnerships with Roche on petrelintide and Boehringer Ingelheim on survodutide, with significant Phase 2 and Phase 3 studies planned for 2026 and this year, respectively.